Panbela announces issuance of new patent in australia patent is for claims of a novel process for the production of sbp-101

Minneapolis, july 17, 2023 (globe newswire) --  panbela therapeutics, inc. (nasdaq: pbla), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced an issue notification for the australian patent 2019213664 titled “methods for producing (6s,15s)-3,8,13,18- tetraazaicosane-6,15-diol”. this patent, developed in collaboration with syngene international ltd.
PBLA Ratings Summary
PBLA Quant Ranking